PL3630093T3 - LECZENIE CHORÓB ZWIĄZANYCH Z NIEPRAWIDŁOWYM FUNKCJONOWANIEM SZLAKU mTOR - Google Patents
LECZENIE CHORÓB ZWIĄZANYCH Z NIEPRAWIDŁOWYM FUNKCJONOWANIEM SZLAKU mTORInfo
- Publication number
- PL3630093T3 PL3630093T3 PL18733182.2T PL18733182T PL3630093T3 PL 3630093 T3 PL3630093 T3 PL 3630093T3 PL 18733182 T PL18733182 T PL 18733182T PL 3630093 T3 PL3630093 T3 PL 3630093T3
- Authority
- PL
- Poland
- Prior art keywords
- dysregulation
- treatment
- diseases associated
- mtor pathway
- mtor
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
- A61K31/36—Compounds containing methylenedioxyphenyl groups, e.g. sesamin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17305620 | 2017-05-30 | ||
| PCT/EP2018/064282 WO2018220068A1 (en) | 2017-05-30 | 2018-05-30 | TREATMENT OF DISEASES ASSOCIATED WITH A DYSREGULATION OF THE mTOR PATHWAY |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3630093T3 true PL3630093T3 (pl) | 2025-12-08 |
Family
ID=59054052
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL18733182.2T PL3630093T3 (pl) | 2017-05-30 | 2018-05-30 | LECZENIE CHORÓB ZWIĄZANYCH Z NIEPRAWIDŁOWYM FUNKCJONOWANIEM SZLAKU mTOR |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20200179335A1 (pl) |
| EP (1) | EP3630093B1 (pl) |
| JP (1) | JP7395358B2 (pl) |
| CA (1) | CA3065417A1 (pl) |
| DK (1) | DK3630093T3 (pl) |
| ES (1) | ES3053709T3 (pl) |
| PL (1) | PL3630093T3 (pl) |
| WO (1) | WO2018220068A1 (pl) |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BE795893A (fr) | 1972-02-28 | 1973-06-18 | Unicler | Derives de (methylene dioxy-3,4 phenyl)-1 dimethyl-4,4 pentene-1, leur preparation et leur application en therrapeutique |
| US7169594B2 (en) * | 2002-08-12 | 2007-01-30 | Regents Of The University Of Michigan | Diagnosis and treatment of diseases arising from defects in the tuberous sclerosis pathway |
| HUE032888T2 (hu) * | 2008-12-08 | 2017-11-28 | Biocodex | Vegyületek és eljárások autizmus spektrum zavarok kezelésére |
| WO2014115764A1 (ja) * | 2013-01-25 | 2014-07-31 | 国立大学法人岡山大学 | 乳酸脱水素酵素阻害剤およびそれを含有する医薬品 |
| GB2531281A (en) * | 2014-10-14 | 2016-04-20 | Gw Pharma Ltd | Use of cannabidiol in the treatment of intractable epilepsy |
-
2018
- 2018-05-30 CA CA3065417A patent/CA3065417A1/en active Pending
- 2018-05-30 WO PCT/EP2018/064282 patent/WO2018220068A1/en not_active Ceased
- 2018-05-30 DK DK18733182.2T patent/DK3630093T3/da active
- 2018-05-30 JP JP2019565866A patent/JP7395358B2/ja active Active
- 2018-05-30 US US16/617,720 patent/US20200179335A1/en active Pending
- 2018-05-30 ES ES18733182T patent/ES3053709T3/es active Active
- 2018-05-30 EP EP18733182.2A patent/EP3630093B1/en active Active
- 2018-05-30 PL PL18733182.2T patent/PL3630093T3/pl unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP3630093B1 (en) | 2025-08-20 |
| DK3630093T3 (da) | 2025-10-20 |
| JP7395358B2 (ja) | 2023-12-11 |
| EP3630093A1 (en) | 2020-04-08 |
| JP2020521782A (ja) | 2020-07-27 |
| US20200179335A1 (en) | 2020-06-11 |
| WO2018220068A1 (en) | 2018-12-06 |
| ES3053709T3 (en) | 2026-01-26 |
| CA3065417A1 (en) | 2018-12-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11202104461XA (en) | Therapeutic methods | |
| GB201709456D0 (en) | Therapeutic agents | |
| LT3122878T (lt) | Terapija mrnr, skirta akių ligų gydymui | |
| PT3658140T (pt) | Combinações de aprocitentan com outros ingredientes ativos para o tratamento de hipertensão resistente | |
| GB201616839D0 (en) | Therapeutic compounds | |
| EP3188721A4 (en) | Human therapeutic agents | |
| GB201603104D0 (en) | Therapeutic agents | |
| ZA201805046B (en) | Therapeutic compounds | |
| GB201716942D0 (en) | Therapeutic compounds | |
| GB201608797D0 (en) | Therapeutic use | |
| PL3129483T3 (pl) | Terapia skojarzona do leczenia chorób autoimmunologicznych | |
| GB201617339D0 (en) | Therapeutic compounds | |
| GB201700526D0 (en) | Therapeutic use | |
| GB201700553D0 (en) | Therapeutic agents | |
| GB201607797D0 (en) | Glaucoma therapy | |
| IL263821A (en) | Medicinal compounds | |
| IL259381B (en) | Mirabegron for the treatment of retinal diseases | |
| EP3474876A4 (en) | TREATMENT OF MORBUS CANAVAN | |
| GB201600376D0 (en) | Novel therapeutic agents | |
| PL3630093T3 (pl) | LECZENIE CHORÓB ZWIĄZANYCH Z NIEPRAWIDŁOWYM FUNKCJONOWANIEM SZLAKU mTOR | |
| GB201620948D0 (en) | Therapeutic agents | |
| GB201616563D0 (en) | Therapeutic agents | |
| GB201819936D0 (en) | Therapeutic methods | |
| GB2558788B (en) | New therapeutic uses | |
| GB201807147D0 (en) | Therapeutic combination |